Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neon Therapeutics

Request full access

Focused on unlocking the full potential of the immune system to recognize and attack cancer

Cambridge, United StatesFounded 2015Biotech & Life Sciences

About Neon Therapeutics

Neon Therapeutics, a company acquired by BioNTech in 2020, operated in the immuno-oncology sector with a focus on developing neoantigen-targeted therapies for cancer treatment. The company was founded in 2013 by a distinguished group of individuals including Nir Hacohen, Stephen Hoge, Eric Lander, Robert Langer, James Allison, Ton Schumacher, and Pardis Sabeti, emerging from stealth mode in 2015. This team brought together extensive expertise in genomics, immunology, and drug delivery, which was foundational to the company's scientific approach.

The core of Neon Therapeutics' strategy was the development of personalized cancer treatments. Their lead candidate, NEO-PV-01, was a personal cancer vaccine custom-designed for each patient based on the unique neoantigens—mutations found exclusively on cancer cells. This vaccine was intended to be used in combination with checkpoint inhibitors to stimulate a tailored immune response against a patient's specific tumor. The company also developed a T-cell therapy program, NEO-PTC-01, which involved extracting, selecting, and expanding a patient's own T-cells that were naturally reactive to their cancer's neoantigens. Beyond personalized therapies, Neon Therapeutics was also advancing a shared neoantigen program, targeting common mutations found across certain cancer patient populations.

Financially, Neon Therapeutics achieved several significant milestones. The company raised a total of $241 million through various funding rounds, including a $106 million Series B financing in 2017. It went on to successfully launch an Initial Public Offering (IPO) in June 2018, raising $100 million. Ultimately, the company's journey culminated in its acquisition by BioNTech in May 2020 for $67 million, a move that integrated Neon's neoantigen expertise and its US-based team into BioNTech's global operations.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
15
Open positions
None listed
Dealroom signal
61.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, AI Applications, DT and LS, science-based
Technology
Artificial Intelligence
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jan 2020 $67M $67M BioNTech —
IPOOther financing Jun 2018 $100M $451M Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Neon Therapeutics website traffic

Latest recorded traffic for Neon Therapeutics is 110 monthly website visits, down 47.6% over the last three months. Neon Therapeutics's team grew 0% over the past year.

Latest monthly visits110 3-month web change-47.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neon Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Neon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Other known investors4 additional known investors

  • BioNTech
  • Broad Institute
  • Dana-Farber Cancer Institute
  • Massachusetts General Hospital
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neon Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.